These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8420593

  • 1. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
    Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL.
    Biol Psychiatry; 1993 Jan 01; 33(1):3-14. PubMed ID: 8420593
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
    Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR.
    Biol Psychiatry; 1995 Aug 01; 38(3):138-49. PubMed ID: 7578657
    [Abstract] [Full Text] [Related]

  • 4. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
    Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL.
    Arch Gen Psychiatry; 1987 Nov 01; 44(11):946-51. PubMed ID: 3675134
    [Abstract] [Full Text] [Related]

  • 5. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
    Broocks A, Pigott TA, Hill JL, Canter S, Grady TA, L'Heureux F, Murphy DL.
    Psychiatry Res; 1998 Jun 02; 79(1):11-20. PubMed ID: 9676822
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low versus standard dose mCPP challenge in obsessive-compulsive patients.
    Erzegovesi S, Martucci L, Henin M, Bellodi L.
    Neuropsychopharmacology; 2001 Jan 02; 24(1):31-6. PubMed ID: 11106873
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
    Stein DJ, Van Heerden B, Wessels CJ, Van Kradenburg J, Warwick J, Wasserman HJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug 02; 23(6):1079-99. PubMed ID: 10621951
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
    de Leeuw AS, Westenberg HG.
    J Psychiatr Res; 2008 Sep 02; 42(11):894-901. PubMed ID: 18533183
    [Abstract] [Full Text] [Related]

  • 15. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S, John JP, Reddy LP.
    Psychoneuroendocrinology; 2001 Feb 02; 26(2):209-23. PubMed ID: 11087965
    [Abstract] [Full Text] [Related]

  • 16. Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats.
    Meert TF, Melis W, Aerts N, Clincke G.
    Behav Pharmacol; 1997 Aug 02; 8(4):353-63. PubMed ID: 9832994
    [Abstract] [Full Text] [Related]

  • 17. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
    Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR.
    Arch Gen Psychiatry; 1989 Jan 02; 46(1):23-8. PubMed ID: 2910220
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls.
    Koreen AR, Lieberman JA, Alvir J, Chakos M.
    Neuropsychopharmacology; 1997 Jan 02; 16(1):61-8. PubMed ID: 8981389
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.